Iron Gate Global Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Iron Gate Global Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-420	Closed	-$2K	–	231
2018 Q3	$2K	Buy	420 +200	+91%	+$1.53K	﹤0.01%	222
2018 Q2	$2K	Buy	+220	New	+$2.25K	﹤0.01%	204

Other funds holding ZYNE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Iron Gate Global Advisors's ZYNE Position: Q4 2018 in Review

Iron Gate Global Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 420 shares — an estimated $2K sold.

Iron Gate Global Advisors first reported a position in ZYNE in Q2 2018 and held it in 2 quarters. The position peaked at $2K in Q3 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

Iron Gate Global Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
Iron Gate Global Advisors sold 420 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $2K.
Iron Gate Global Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 2 quarters.
Iron Gate Global Advisors's Zynerba Pharmaceuticals, Inc position peaked at $2K in Q3 2018.
62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Iron Gate Global Advisors's 13F filing for Q4 2018, filed 19 Feb 2019.